TrialGynecologic oncology2024

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.

Joyce F Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.